← Eichor
Study identifier: NCT06568939 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer  ·  Sponsor: AbbVie

PhasePhase 2
Planned participants150
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide. Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

This description comes directly from the study's public registry record.

Talk to the study team

ABBVIE CALL CENTER  ·  844-663-3742  ·  abbvieclinicaltrials@abbvie.com

Always discuss trial participation with your own doctor first.

Locations (80)

Ironwood Cancer and Research Center /ID# 276370Chandler, Arizona, United StatesRecruiting
University of Arkansas for Medical Sciences /ID# 272923Little Rock, Arkansas, United StatesRecruiting
Valkyrie Clinical Trials /ID# 271322Los Angeles, California, United StatesRecruiting
Yale New Haven Hospital /ID# 271584New Haven, Connecticut, United StatesRecruiting
Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899Jacksonville, Florida, United StatesRecruiting
Ocala Oncology Center /ID# 273697Ocala, Florida, United StatesRecruiting
Memorial Hospital West /ID# 270313Pembroke Pines, Florida, United StatesRecruiting
Comprehensive Hematology Oncology /ID# 270422St. Petersburg, Florida, United StatesRecruiting
Florida Cancer Specialists - North /ID# 271995St. Petersburg, Florida, United StatesRecruiting
Florida Cancer Specialists - East /ID# 271993West Palm Beach, Florida, United StatesRecruiting
University Cancer & Blood Center /ID# 270969Athens, Georgia, United StatesRecruiting
Northwest Georgia Oncology Centers /ID# 275374Marietta, Georgia, United StatesRecruiting

+ 68 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06568939